Option chain shows key data for LOTUS CREEK EXPL INC by LOTUS CREEK EXPL INC's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for LOTUS CREEK EXPL INC by LOTUS CREEK EXPL INC.

LOTUS CREEK EXPL INC by LOTUS CREEK EXPL INC (OTC:LTCEF) Stock, Option Chain

LOTUS CREEK EXPL INC by LOTUS CREEK EXPL INC

Goldman Sachs analyst Leah Jordan downgrades Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from Buy to Neutral and lowers the price target from $33 to $26.

News

Downgrades

Price Target

Analyst Ratings

Goldman Sachs Downgrades Conagra Brands to Neutral, Lowers Price Target to $26

WIIM

TRDA

Entrada Therapeutics shares are trading higher after the company announced that the FDA removed the clinical hold on ENTR-601-44 and that it has obtained clearance status.

TD Securities analyst Andrew Charles reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Buy and maintains $490 price target.

Reiteration

TD Securities Reiterates Buy on Domino's Pizza, Maintains $490 Price Target

Global life and health reinsurance entity Reinsurance Group of America, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Monday.
The company has reached an agreement with Equitable Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) to reinsure a wide <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43907362/rga-announces-reinsurance-transaction-with-equitable-holdings" rel="noreferrer noopener">range of life insurance products</a>.
Under the terms of the deal, RGA is reinsuring&nbsp;75%&nbsp;of Equitable&#8217;s in-force life insurance liabilities. The block includes approximately&nbsp;$18 billion&nbsp;of general account reserves and&nbsp;$14 billion&nbsp;of separate account reserves.
This deal is set up to allow RGA to invest $1.5 billion in capital at the closing. It is expected to generate returns within RGA&#8217;s projected range, while also providing a notable increase in the company&#8217;s adjusted operating earnings per share.
Furthermore, the agreement expands RGA&#8217;s partnership with Equitable across various sectors, including underwriting, product creation, distribution, and investment management.
&#8220;This partnership is an example of our capacity to provide creative solutions and technical expertise that support both sides of the balance sheet, and it is a prime example of how the execution of our Creation Re strategy can address our clients&#8217; current and future needs,&#8221; said Executive Vice President, Head of the Americas, RGA, Ron Herrmann.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success" rel="noreferrer noopener">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a>
The deal is expected to contribute around $70 million to adjusted operating income before taxes in 2025. This amount is anticipated to increase to between $160 million and $170 million in 2026, eventually stabilizing at around $200 million each year thereafter.
&#8220;Our strong financial position enables us to capitalize on this opportunity with Equitable, and the transaction is expected to meaningfully contribute to RGA&#8217;s earnings per share, with anticipated attractive returns on capital,&#8221; said Executive Vice President, Chief Financial Officer, RGA, Axel André.
RGA intends to fund the transaction with surplus capital and, if necessary, proceeds from debt financing, contingent on market conditions. The transaction is set to close in mid-2025, pending regulatory approval and other customary closing conditions.
The deal is expected to create more than $2 billion in value for Equitable Holdings, encompassing a favorable ceding <a target="_blank" href="https://www.benzinga.com//node/43907593" rel="noreferrer noopener">commission and the release of capital.</a>
Also, Equitable plans to execute $500 million of incremental share repurchases, above the company&#8217;s 60-70% payout ratio target, following the close of the transaction.
Additionally, Equitable announced its intention to <a target="_blank" href="https://www.benzinga.com//node/43907646" rel="noreferrer noopener">increase its ownership stake in AB</a> through a tender offer to purchase up to $1.8 billion of units of AllianceBernstein Holding L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>)
Price Action: RGA shares are trading higher by 3.55% at $196.11 in premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43887830/openai-expands-operator-ai-agent-to-multiple-countries" target="_blank" rel="noreferrer noopener">OpenAI Expands Operator AI Agent To Multiple Countries</a></li>
</ul>
Photo via Shutterstock.

Equities

Asset Sales

General

Equitable Inks Reinsurance Deal With RGA And Plans To Boost Stake In AllianceBernstein: Details

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The formation of OSDC coincides with formal strategic options initiatives to create value from the Company's leading-edge, patented silicone dioxide-based, pH sensitive tunable antibody drug conjugates (tADC) &amp; other tunable drug conjugates (tDC) platforms. The Company has initiated discussions with clinical-stage ADC therapeutics companies in the U.S., China and other jurisdictions to form joint ventures (JVs) pairing those companies' clinical-stage assets with certain assets from the tADC and/or tDC platforms and spinning the JVs into standalone public companies. If successful, OS Therapies intends to provide stock dividends of the public JVs to shareholders.
The OST-tADC and OST-tDC technologies are centered around the Company's proprietary next-generation tunable Antibody Drug Conjugate (tADC) and tunable Drug Conjugates (tDC) platforms. These advanced technologies incorporate pH-sensitive silicon-based linkers: SiLinkers&#x2122; to link the targeting antibodies (or antibody fragments) and therapeutic moieties together while coating the entire package with pH sensitive coating. This strategy can release multiple therapeutic agents selectively within the tumor and tumor microenvironment, which have lower pH levels than the rest of the body. This approach aims to maximize the therapeutic effects while minimizing damage to healthy cells.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bccresearch.com%2Fmarket-research%2Fpharmaceuticals%2Fantibody-drug-conjugates-markets-report.html%3Fsrsltid%3DAfmBOoqRPnbxc1SPE0lx3HkAmQ-I2X4xd3bWqvtaZu1wAT7gR0oCGUkb&amp;esheet=54212694&amp;newsitemid=20250224482242&amp;lan=en-US&amp;anchor=BCC+Research&amp;index=1&amp;md5=dda6f15610fa07a596439cc152c306cc">BCC Research</a> estimates that the global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.

Dividends

OSTX

OS Therapies Launches Subsidiary to Advance Tunable Antibody Drug Conjugates, Plans Stock Dividends for Shareholders

Goldman Sachs analyst Leah Jordan initiates coverage on Smithfield Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFD#NASDAQ">SFD</a>) with a Buy rating and announces Price Target of $32.

Initiation

Goldman Sachs Initiates Coverage On Smithfield Foods with Buy Rating, Announces Price Target of $32

Barclays analyst David Anderson maintains Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) with a Overweight and raises the price target from $48 to $50.

Barclays Maintains Overweight on Tenaris, Raises Price Target to $50

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy and maintains $9 price target.

CRDL

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

Target Hospitality shares are trading lower after the company announced it lost a key government contract and withdrew its FY25 guidance.

DPZ: -4% &#x7C; <a href="https://www.benzinga.com//node/43908406">Domino's Pizza shares are trading lower after the company reported worse-than-expected Q4 financial results. It also proposed a 15% dividend hike.</a>
&nbsp;
AAPL: -1.5% &#x7C; <a href="https://www.benzinga.com//node/43907712">Apple Commits $500 Billion to US Investment, Focuses on AI and Silicon Innovation</a>
&nbsp;
U: -7% &#x7C; <a href="https://www.benzinga.com//node/43909035">Unity Software shares are trading lower. The company announced a $500 million convertible senior note offering.</a>

Movers

Trading Ideas

AAPL

Market-Moving News for February 24th

HC Wainwright &amp; Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Buy and maintains $21 price target.

ORIC

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target

GDS Holdings shares are trading lower after Jefferies downgraded the stock from Buy to Hold.

RIVN

Rivian Automotive shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform and cut its price target from $13 to $10.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $48 price target.

PRTA

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $48 Price Target

On February&nbsp;24, 2025, Leidos Holdings, Inc. (the "Company") announced it has entered into an accelerated share repurchase agreement (the "ASR Agreement") to repurchase $500&nbsp;million of the Company's common stock. These repurchases will be conducted under the Company's ongoing share repurchase authorization.
Pursuant to the ASR Agreement, the Company made an initial payment of $500&nbsp;million to the counterparty financial institution on February&nbsp;20, 2025 and received on the same day initial deliveries of approximately 3&nbsp;million shares of the Company's common stock from the counterparty. The final number of shares to be repurchased by the Company will be based on the volume-weighted average stock price of the Company's common stock during the term of the ASR Agreement, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR Agreement. At settlement, under certain circumstances, the counterparty may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to the counterparty. The final settlement under the ASR Agreement is expected during the second quarter of 2025, subject to an earlier completion at the counterparty's option.

Buybacks

LDOS

Leidos Announces $500M Accelerated Share Repurchase Agreement, Buys Back 3M Shares, Final Settlement Expected in Q2 2025

Most people assume that crypto's most popular financial instruments are tokens, but index funds are gaining significant traction. In traditional finance (TradFi), index-based funds have historically outperformed single-asset funds in terms of assets under management (AUM), providing investors with diversified exposure while mitigating risk.
While crypto ETFs, particularly <a href="https://www.sec.gov/newsroom/speeches-statements/gensler-statement-spot-bitcoin-011023">Bitcoin ETFs approved by the Securities and Exchange Commission (SEC) in January 2024</a>, have dominated recent market discussions, index funds offer a broader approach to digital asset investing. Instead of relying on the performance of a single asset, index funds track baskets of assets, creating the diversification that investors have long favored in traditional markets. 
In crypto, this approach holds similar potential. Instead of focusing on a single token like Bitcoin or Ethereum, index funds track multiple high-performing digital assets, offering exposure to the broader market while reducing concentration risk. The Bitwise 10 Crypto Index Fund was one of the first such crypto indexes, launched in 2017, and Fidelity and Bloomberg soon followed with its Bloomberg Galaxy Crypto Index in 2018.
As institutional adoption grows, multi-token index funds that take their unique approach to tracking, benchmarking, and reflecting the overall crypto sector could play a key role in bridging traditional investment strategies with the digital asset space.
<h2 class="wp-block-heading">Indexes spare the hassle &#8211; and risk &#8211; of investing in individual coins</h2>
The abundance of information about a coin &#8211; spread across white papers, discussion boards, social media platforms, and messaging apps &#8211; is difficult to keep up with for one coin, let alone the 1000s of digital assets at any given time. While ETFs save investors the inconvenience of buying, storing, and securing $BTC or other coins with forthcoming ETFs, investors must keep up with this real-time information firehose to manage their portfolios.
When there are many ETFs on the market, investors need to sift through piles of information before deciding which one to ultimately purchase. This is burdensome for most retail investors who simply want some exposure to crypto without getting into the technical details.&nbsp;
From this viewpoint, crypto indexes are a much better option: Investors can defer to the collective growth of a handful of top coins, eliminating the need to perform constant, extensive research on any one coin or ETF.
<h2 class="wp-block-heading">Indexes alleviate users from having to trade short-term </h2>
When investing stocks, short-term trading is often necessary. For instance, if you held shares of Nvidia ($NVDA), you might have felt compelled to buy or sell after the stock dropped following the Deepseek announcement.
In contrast, if you are an investor in the S&amp;P 500, which includes $NVDA, you would not need to respond to any market news. You could buy shares in the S&amp;P 500 and count on the overall growth of the market to withstand any changes to a single stock. Such investors can rest easy, knowing that their investment will always be bullish in the long-term (the S&amp;P boasts an average annual return of over <a href="https://www.investopedia.com/ask/answers/042415/what-average-annual-return-sp-500.asp">10% going back to 1957</a>).
Crypto indexes will be attractive in the same way. Instead of having to regularly take action on a specific token position, investors can simply buy shares in a crypto index and leave them untouched for the long-term. In the parlance of the crypto community, they can "hodl." Such investors can count on the continued growth of crypto to take their shares to new heights over time.
<h2 class="wp-block-heading">Indexes protect investors from the risks associated with FOMO </h2>
The fear of missing out (FOMO) is a real problem in crypto. When investors sit on the sidelines and see peers make money from different financial instruments, they may be prone to jump in and make ill-advised decisions.
FOMO is rampant now with meme coins, which Solana has made easier to launch than ever. A few cycles ago, there was also FOMO for non-fungible tokens and even play-and-earn tokens. All of these instruments are highly volatile. For example, the $SQUID token plummeted 99% in <a href="https://www.bbc.com/news/business-59129466">value in a matter of minutes</a>, while once popular NFT collections, <a href="https://www.theguardian.com/sport/2025/jan/14/almost-10000-images-of-tennis-balls-plunge-up-to-90-in-value-as-australian-open-appears-to-ditch-nfts?utm_source=chatgpt.com">such as those of tennis balls by the Australian Open</a>, were down by 90%.&nbsp;
Indexes can prevent investors from risky FOMO-based decision-making because they already have broad exposure. For example, they would not need to invest in meme coins because most popular indexes include Solana, the preferred blockchain for such assets. Similarly, they would not need to purchase any single NFTs because indexes always have Ethereum, the market leading blockchain for them.&nbsp;
Indexes will likewise give investors exposure to other major trends in the future, all without having to buy into individual assets that are highly risky on their own.
<h2 class="wp-block-heading">Indexing your Crypto Exposure&nbsp;</h2>
As crypto investment vehicles evolve, indexes represent the next logical step in providing retail investors with diversified, low-maintenance exposure to the market. While ETFs solve the challenge of buying and storing individual tokens, they still require investors to stay informed about specific assets. Indexes, on the other hand, simplify the investment process by spreading risk across multiple top-performing cryptocurrencies, much like how traditional stock indexes provide long-term stability.
By mitigating the risks of short-term trading and FOMO-driven decisions, indexes offer a more resilient approach to crypto investing. Whether the market shifts toward new trends or faces periods of volatility, indexes allow investors to participate in crypto's overall growth without the burden of constant research and rebalancing. Just as stock indexes have become a cornerstone of traditional investing, crypto indexes are poised to become a preferred vehicle for long-term, diversified exposure to the digital asset space.&nbsp;
Crypto, in short, operates like a book: The best guide is often the index.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

The Rise of Passive Investing: How Crypto is Evolving for Retail Investors

Westlake shares are trading lower after the company reported worse-than-expected Q4 financial results.

Unity Software shares are trading lower. The company announced a $500 million convertible senior note offering.

A. Preview of timsTOF Ultra 2 system with novel Athena Ion Processor (AIP):
- Improves protein group identification in single-cell proteomics (SCP) by 15%-20%, and peptide identifications in SCP by 20%-25%
-Advances immunopeptidomics with 15%-20% more immunopeptide identifications
B. Launch of DeutEx&#x2122; software for hydrogen-deuterium exchange (HDX-MS) analysis
C. OmniScape&#x2122; 2025b: a breakthrough in top-down protein sequencing software
D. Advances in ProteoScape&#x2122; and Glycoproteomics software capabilities
E. Advances in TwinScape&#x2122; for cloud-based, AI-enabled proteomics quality monitoring

BRKR

Bruker Unveils 4D-Proteomics Breakthrough At US HUPO: Enhanced Single-Cell and Immunopeptidomics With timsTOF Ultra 2 And Athena Ion Processor

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $53 price target.

Comments

LOTUS CREEK EXPL INC by LOTUS CREEK EXPL INC

LOTUS CREEK EXPL INC by LOTUS CREEK EXPL INC (LTCEF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga